Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery by Kostan W. Reisinger et al.
ORIGINAL ARTICLE – THORACIC ONCOLOGY
Loss of Skeletal Muscle Mass During Neoadjuvant
Chemoradiotherapy Predicts Postoperative Mortality
in Esophageal Cancer Surgery
Kostan W. Reisinger, MD1,2, Joanna W. A. M. Bosmans, MD1,2, Martine Uittenbogaart, MD3, Abdulaziz Alsoumali,
GS1,3, Martijn Poeze, MD, PhD1,2, Meindert N. Sosef, MD, PhD3, and Joep P. M. Derikx, MD, PhD1,2
1Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands; 2NUTRIM School for
Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands; 3Department of Surgery,
Atrium Medical Center, Heerlen, The Netherlands
ABSTRACT
Background. Esophageal surgery is associated with
complications and mortality. It is highly important to de-
velop tools predicting unfavorable postoperative outcome.
Esophageal cancer and neoadjuvant chemoradiotherapy
(CRT) induce skeletal muscle wasting, which leads to di-
minished physiologic reserves. The purpose of this study
was to investigate whether the degree of muscle mass lost
during neoadjuvant CRT predicts postoperative mortality.
Methods. A total of 123 consecutive patients undergoing
surgery for esophageal malignancy in the period
2008–2012 were included, of whom 114 received neoad-
juvant CRT. Skeletal muscle mass was measured on
routinely performed CT scans by assessing L3 muscle in-
dex (according to the Prado method) before and after
neoadjuvant CRT, and the amount of muscle mass lost
during neoadjuvant CRT (muscle loss index) was calcu-
lated. It was investigated whether this amount was
associated with postoperative 30-day or in-hospital mor-
tality and morbidity.
Results. In the complete cohort, no significant association
between loss of muscle mass and mortality was found.
However, skeletal muscle mass was significantly lower in
patients with stage III–IV tumors compared with stage I–II
tumors, prior to neoadjuvant CRT. In the stage III–IV
subgroup, the amount of muscle mass lost during neoad-
juvant CRT was predictive of postoperative mortality: -
13.5 % (standard deviation 6.2 %) in patients who died
postoperatively compared with -5.0 % (standard deviation
8.3 %) in surviving patients, p = 0.02.
Conclusions. Measurement of muscle mass loss during
neoadjuvant chemoradiotherapy may provide a readily
available and inexpensive assessment to identify patients at
risk for developing unfavorable postoperative outcome
after resection of esophageal malignancies, especially in
patients with stage III–IV tumors.
Complications after esophageal resection present a se-
rious problem: 26–41 % of patients develop major adverse
events; the majority of which are cardiopulmonary and
infectious complications or anastomotic leakage. Mortality
rates are 4–10 %.1 Therefore, it is imperative to develop
tools that predict unfavorable postoperative outcome
adequately. The assessment of sarcopenia may indicate
whether complications are likely to arise. Sarcopenia is
defined as a syndrome characterized by progressive and
generalized loss of skeletal muscle mass and strength,
which increases the risk of adverse health-related out-
comes, such as impaired physical ability, decreased quality
of life, and mortality.2,3 We showed before that in col-
orectal surgery, sarcopenia as an important element of
functional compromise is associated with postoperative
mortality.4 Neoadjuvant chemoradiotherapy (CRT) induces
significant sarcopenia in esophageal cancer patients.5
Moreover, esophageal cancer can further deteriorate
skeletal muscle mass by causing cachexia. Sarcopenia is
associated with complications following surgery.6,7
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Furthermore, sarcopenic obesity, defined as high body
mass index and low muscle tissue on CT scan, is hy-
pothesized to be a predictor of unfavorable oncologic and
surgical outcomes.8,9 It is known that both sarcopenia and
obesity are associated with chronic inflammation, which
could explain the high incidence of postoperative compli-
cations in sarcopenic obese patients.10,11 In addition, these
patients are often not seen as ‘‘at risk,’’ because normal
body mass index due to high fat mass camouflages
sarcopenia.
A readily available instrument to quantify skeletal
muscle mass is CT-based muscle area measurement at the
level of the lumbar three vertebral landmark, which can be
accomplished by using open-source software.12,13
Although low preoperative muscle mass measured on CT
scans could not be associated with mortality and length of
hospital stay in patients undergoing esophageal surgery, the
amount of muscle mass loss induced by neoadjuvant CRT
may be a more dynamic predictor of postoperative out-
come.5 Increased muscle loss before surgery presumably
reflects high metabolic stress due to malnutrition, cachexia,
tumor load, or inflammation, negatively affecting the
metabolic response to major gastrointestinal surgery. In
this study, it was hypothesized that the amount of muscle
mass loss during neoadjuvant CRT predicts postoperative
mortality after esophageal resection. The primary purpose
of the study was to measure whether the amount of muscle
mass lost during neoadjuvant CRT in patients undergoing
esophageal resection was associated with postoperative
mortality. The secondary goal of the study was to measure
whether sarcopenic obesity and fat loss over the course of
neoadjuvant CRT, using a pre- and post-CRT time point,
was associated with postoperative mortality.
METHODS
Patients
All patients who underwent resection of esophageal
cancer in a single teaching hospital from January 2008 until
January 2012 were enrolled in a prospectively maintained,
digital database. Data included characteristics of the pri-
mary tumor and oncologic staging, specifications of
surgical treatment, chemotherapy, radiotherapy, and post-
operative complications. All patients who received
neoadjuvant CRT were included in this study. Neoadjuvant
CRT consisted of three cycles of cisplatin/5-fluorouracil
(CF) or five cycles of paclitaxel/carboplatin (PC), all with
concurrent radiotherapy, or consisted of three cycles of
epirubicin/cisplatin/capecitabine (ECC), also with concur-
rent radiotherapy in some patients. A routine total body
PET/CT scan before neoadjuvant CRT (preCRT) and after
neoadjuvant CRT (postCRT) was performed, as standard
care for all patients diagnosed with esophageal cancer.
After a multidisciplinary meeting, which took place
weekly, patients were admitted to the neoadjuvant CRT
protocol, generally meaning that treatment started within
2 weeks after PET/CT. The second PET/CT was performed
directly after neoadjuvant CRT, following the same pro-
tocol in all patients. The average time between the first and
second PET/CT was 111 days [standard deviation (SD),
13 days]. The variation was mostly due to neoadjuvant
CRT taking longer because of side-effects. Patients were
closely monitored by a dietician from the moment of di-
agnosis until hospital discharge after surgery, and
malnutrition was screened for using the Short Nutritional
Assessment Questionnaire (SNAQ). Adequate oral intake
was verbally encouraged, and if nutritional depletion was
present, patients received protein-rich and lipid-rich drinks.
A gastric or jejunal feeding tube was placed in patients
with esophageal stenosis. Furthermore, physical activity
was stimulated by counseling or by active preconditioning
by an expert physiotherapist. The study was conducted
with approval from local medical ethical committees and
according to the revised version of the Declaration of
Helsinki (October 2008, Seoul). The principles of good
clinical practice (GCP) were followed during this study.
Postoperative Mortality
The primary clinical outcome of the study was postop-
erative mortality. This was defined as mortality within
30 days or within hospital admission.
CT-Based Muscle and Fat Measurements
CT-based measurements were performed using Osirix
Version 3.3 (32-bit; http://www.osirix-viewer.com) by a
researcher who was blinded from outcome. The cross-
sectional skeletal muscle surface (cm2) as measure of sar-
copenia was measured at the level of the third lumbar
vertebra (L3) on two consecutive transversal slices on
which both vertebral spines were visible.13 The ‘‘Grow
Region (2D/3D Segmentation)’’ tool in the menu of the
program facilitated to select automatically all skeletal
muscle mass in one slice. In the same manner, L3 total
adipose tissue was composed of all adipose tissue on the L3
level, including subcutaneous adipose tissue, visceral adi-
pose tissue, and intramuscular adipose tissue. Visceral and
subcutaneous fat were measured after manual adjustment
to ensure no excessive tissue was included in the mea-
surements. The average surface (cm2) of the two
consecutive slices was used for the analyses. The distinc-
tion between different tissues was based on Hounsfield
units (HU) with a threshold range of -29 to ?150 HU used
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for skeletal muscle and a range of -190 to -30 HU for fat
tissue.7,12 Muscles measured were: psoas, quadratus lum-
borum, paraspinal, transverse abdominal, external oblique,
internal oblique, and rectus abdominis muscles. Hand-ad-
justment of the selected areas was performed if necessary
and the values of muscle or fat area were automatically
calculated by Osirix13
Sarcopenia and Muscle Loss Index
The L3 muscle area surfaces were normalized for patient
height to calculate the L3 muscle index and expressed in
cm2/m2. Patient height and weight were measured by a
nurse at admission to the hospital at the time of diagnosis.
The cutoff values used for sarcopenia were 52.4 cm2/m2
for men and 38.5 cm2/m2 for women, based on the method
of Prado et al.12 Previous data showed high interobserver
agreement with kappa of sarcopenia assessment by CT
image analysis using Osirix of 0.87 (95 % confidence
interval 0.82–0.93) and Bland–Altman analysis produced
95 % limits of agreement: -5.9 to 8.7 %.14
The muscle loss index (MLI), as a measure of muscle
mass loss during chemoradiotherapy, was calculated as
follows: (postCRT L3 index—preCRT L3 index)/preCRT
L3 index 9 100 %.
Visceral Obesity and Sarcopenic Obesity
Sex-specific cutoff values for visceral obesity were
163.8 cm2 for men and 80.1 cm2 for women.15 For sar-
copenic obesity, two separate definitions were used. The
first definition was the combination of sarcopenia and
visceral obesity (sarcopenic visceral obesity); the second
definition was the combination of sarcopenia and obesity
based on BMI[ 30 kg/m2 (sarcopenic obesity). Visceral
obesity and sarcopenic obesity were calculated at both time
points (preCRT and postCRT), using height and weight
values recorded at the time of diagnosis.
Statistical Analysis
Normality was tested using Kolmogorov–Smirnov.
Frequencies are presented as absolute numbers and per-
centages. Continuous data are presented as mean and
standard deviation (SD). Differences between groups were
analyzed with the Pearson v2 test for dichotomous pa-
rameters. Paired t test was used for between group
comparison of preCRT and postCRT continuous data. In-
dependent samples t test was used for between group
comparison of continuous data on a single time point
(preCRT or postCRT) and for between-group comparison
of MLI and fat loss. Receiver operating characteristic
(ROC) curves were used to calculate accuracy of the
relative L3 index decrease to predict postoperative mor-
tality. The ideal cutoff value for predicting mortality was
defined as the cutoff value with maximum sum of sensi-
tivity and specificity. Overall diagnostic accuracy was
represented by the area under the curve (AUC). Two-tailed
p values\0.05 were considered significant. All statistical
analyses were performed using SPSS 20.0 (SPSS Inc,
Chicago, IL).
RESULTS
Patients and L3 Index During Chemoradiotherapy
A total of 123 patients were included, of whom 101
(82 %) were males; 114 patients received neoadjuvant
CRT. Both a preCRT and postCRT CT scan were available
in 96 patients. Patient, tumor, and operation characteristics
are presented in Table 1. An explanatory flowchart of pa-
tients, including those receiving CRT and availability of
CT scans, is presented in Diagram 1. Sarcopenia was
present in 60 of 108 patients (56 %) before CRT and in 74
of 111 patients (67 %) after CRT. Concomitantly, the mean
L3-index decreased significantly during CRT, which was
measured in patients with both a preCRT and a postCRT
CT scan [50.9 (SD, 8.5) cm2/m2 to 48.4 (8.5) cm2/m2,
p\ 0.001; Fig. 1a]. In male subjects, the L3-index de-
creased from 53.4 (7.8) to 49.5 (7.9) cm2/m2, p\ 0.001,
and in female subjects the L3-index decreased from 42.7
(5.4) to 39.7 (4.4) cm2/m2, p = 0.02. Mortality within
30 days or within hospital admission was 11 of 123 (9 %)
in the total cohort and 6 of 62 (10 %) in patients with stage
III-IV tumors. Of note, only stage IV patients who re-
sponded well to CRT and were classified as stage III after
CRT were eligible for surgery. Of patients with both a
preCRT and postCRT CT scan, mortality rates were 9 of 96
(9 %) and 5 of 52 (10 %), respectively. Causes of mortality
are listed in Table 2.
Influence of Tumor Characteristics on the L3 Index
The mean L3 index was significantly lower before CRT
began in patients with advanced (stage III–IV) tumors
compared with localized tumors [49.1 (8.4) cm2/m2 and
52.9 (8.4) cm2/m2, p = 0.02; Fig. 1b]. (Male subjects: 54.3
(7.8) compared with 51.5 (7.6) cm2/m2, p = 0.02; female
subjects: 44.8 (7.5) compared with 40.0 (3.3) cm2/m2,
p = 0.03), respectively.) In both stage III–IV and stage I–II
tumors, the L3 index decreased significantly during CRT.
L3 indices were not different between patients with ade-
nocarcinoma and patients with squamous cell carcinoma,
and there was no difference between the amount of sar-
copenic patients between carcinoma types.
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L3 Index Decrease as a Predictor of Mortality
The MLI was not predictive for postoperative mortality
directly related to complications in the total study
population; -8.6 % (7.6 %) in patients who died postop-
eratively compared with -7.0 % (8.0 %; p = 0.57) in
surviving patients. Because L3 indices differed sig-
nificantly between stage III–IV and stage I–II disease, these
groups were analyzed separately. In patients with stage I-II
tumors, MLI was not different between patients with and
those without postoperative mortality, respectively: -
2.5 % (3.6 %) and -9.4 % (7.1 %), p = 0.07. In patients
with stage III–IV tumors, patients who died postoperatively
showed significantly higher decrease in MLI [-13.5 %
(6.2 %)] compared with surviving patients [-5.0 %
(8.3 %), p = 0.02; Figs. 2a, b]. An analysis for female
TABLE 1 Patient, tumor, and operation characteristics
Complete cohort (n = 123) Patients with preCRT and postCRT CT scans (n = 96)
Number of patients Mean (SD) Number of patients Mean (SD)
Sex
Male 101 (82.1 %) 80 (83.3 %)
Female 22 (17.9 %) 16 (16.7 %)
Age (year) 63 (10) 63 (9.2)
[70 32 (26 %) 23 (24 %)
BMI (kg/m2) 24.7 (4.2) 24.7 (4.3)
\18.5 12 (9.7 %) 10 (10.4 %)
18.5–24.9 54 (43.9 %) 42 (43.8 %)
25.0–29.9 44 (35.8 %) 32 (33.3 %)
C30.0 13 (10.6 %) 12 (12.5 %)
Length of hospital stay (days) 26 (33) 26 (35)
ASA
I 30 (25.4 %) 28 (29.2 %)
II 52 (44.1 %) 44 (45.8 %)
III 36 (30.5 %) 24 (25.0 %)
Stage
I–II 61 (49.6 %) 44 (45.8 %)
III–IV 62 (50.4 %) 52 (54.2 %)
Time between preCRT CT and postCRT CT (days) 111 (17) 111 (17)
Time between postCRT CT and operation (days) 33 (19) 32 (19)
Type of chemotherapy
CF 99 (86.8 %) 84 (87.5 %)
ECC 6 (5.2 %) 3 (3.1 %)
PC 9 (7.9 %) 9 (9.4 %)
Tumor type
Adenocarcinoma 100 (81.3 %) 82 (85.4 %)
Squamous cell carcinoma 23 (18.7 %) 14 (14.6 %)
Tumor location
Proximal esophageal 1 (0.9 %) 16 (16.7 %)
Mid esophageal 20 (17.9 %) 53 (55.3 %)
Distal esophageal 57 (48.7 %) 21 (21.9 %)
Junctional 29 (24.8 %) 6 (6.3 %)
Gastric 10 (8.5 %) 44 (45.8 %)
Type of surgery
Transthoracic 58 (47.2 %) 52 (54.2 %)
Transhiatal 65 (52.8 %) 664 (1,085)
Blood loss (mL) 664 (970)
ASA American Society of Anesthesiologists, CRT chemoradiotherapy, CF cisplatin/5-fluorouracil, ECC epirubicin/cisplatin/capecitabine, PC
paclitaxel/carboplatin, BMI body mass index, calculated at time of diagnosis
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patients could not be done, because there were no stage III–
IV female patients with postoperative mortality in this
cohort. Analysis of only male patients yielded comparable
results.
MLI was not associated with incidence of specific
complications (anastomotic leakage, abscess, empyema,
sepsis, postoperative ileus, surgical site infections, pneu-
monia, and pneumothorax) or with length of hospital stay.
To determine diagnostic accuracy of the MLI to detect
postoperative mortality in patients with stage III–IV dis-
ease, ROC curve analysis was done (Fig. 2c). An optimal
cutoff point of -13.2 % was found with sensitivity 80 %,
specificity 85 %, positive likelihood ratio 5.33 [95 %
confidence interval (CI), 2.5–11.0], and negative likelihood
ratio 0.24 (95 % CI 0.04–1.4; p = 0.03). The area under
the ROC curve was 0.80 (95 % CI 0.64–0.96).
Sarcopenic Obesity as a Predictor of Postoperative
Mortality
At the preCRT time point, 16 patients were defined as
having sarcopenic visceral obesity (sarcopenia and visceral
obesity) and two patients were defined as having sar-
copenic obesity (sarcopenia and high BMI; Table 3). At the
postCRT time point, these were 20 and 2 patients, re-
spectively. Sarcopenic visceral obesity was not associated
with postoperative mortality (preCRT, p = 0.79; postCRT,
p = 0.46). Furthermore, sarcopenic obesity was not asso-
ciated with mortality (preCRT, p = 0.66; postCRT,
p = 0.66). When patients with stage I–II tumors and those
with stage III–IV tumors were analyzed separately, com-
parable results were found.
Fat Loss as a Predictor of Postoperative Mortality
In contrast to loss of muscle mass, total fat loss was not
associated with postoperative mortality in the complete
study cohort, nor when stage I–II disease and stage III-IV
disease were analyzed separately (stage I–II: -9.1 %
(20.0 %) in patients who died postoperatively compared
with -4.8 % (24.2 %) in surviving patients, p = 0.74;
stage III–IV: -21.8 % (23.4 %) compared with -3.0 %
(38.2 %), respectively, p = 0.29). Comparable results were
found for subcutaneous fat and visceral fat.
DISCUSSION
This study confirms the loss of muscle mass during
neoadjuvant CRT in patients who undergo resection of
esophageal malignancies. This is the first study that shows
that loss of muscle mass, as measured on routinely obtained
CT scans, is associated with postoperative mortality in
patients with advanced tumors. This may provide a readily



































































FIG. 1 L3 muscle index before and after neoadjuvant CRT in patients undergoing esophageal surgery. a Patients with both a preCRT and a
postCRT CT scan (n = 96). b By tumor stage: stage III–IV (n = 52) versus I–II (n = 44)
TABLE 2 Causes of mortality
Number of patients
Anastomotic leakage 5
Pneumonia and respiratory failure 3
Intestinal ischemia 1
Cardiac ischemia 1
Postoperative pulmonary bleeding 1
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risk for developing unfavorable postoperative outcome.
Intriguingly, none of the anthropometric parameters at a
single time point were significantly associated with post-
operative outcome, but rather the dynamic loss during
neoadjuvant CRT. It is therefore important to calculate the
MLI, as a difference between preCRT and postCRT.
Although hypothesized, sarcopenic obesity was not asso-
ciated with postoperative mortality in this study. The MLI
seemed to be of more importance than the combination of
sarcopenia and high BMI. No association could be found
between loss of fat mass of any type and postoperative
mortality. The mortality rate in this study is comparable to
reported rates in recent literature, where percentages vary
from 5 to 10 %.16,17
The application of patient-tailored approaches is up-
coming in oncologic health care.18 In this context,
measurements of the physical ability to recover adequately
from therapeutic hits, such as surgery, is vital, particularly
in the tumor-bearing patient in whom metabolic and nu-
tritional resources are generally depleted. Considering the
striking impact of metastasized disease on physiological
depletion, patients with stage III and IV tumors are more
prone to loss of reserves, manifesting as cachexia, which
includes loss of muscle mass. The current data reflect this
effect by lower L3 muscle index in patients with stage III–
IV disease. This loss in muscle tissue is the result of both
increased muscle protein degradation and reduced muscle
synthesis. Tumors, especially in more advanced stages,
may increase host’s resting energy expenditure (REE).
Ravasco et al. found an elevated REE in patients with stage
III–IV colorectal tumors.19 Furthermore, Bachmann et al.
showed that pancreatic cancer patients with cachexia had a
higher rate of more progressed tumor stages and a worse
nutritional status.20 Selection of patients with increased
40
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FIG. 2 Loss of muscle mass measured as decrease of L3 muscle
index in patients with advanced (stage III–IV) tumors. a L3 indices
before and after CRT in surviving patients (n = 47) and patients who
die from postoperative complications (n = 5). b Relative L3 index
decrease in surviving patients and patients who die from postop-
erative complications. c ROC curve of relative L3 index decrease to
predict postoperative mortality
4450 K. W. Reisinger et al.
risk for poor postoperative outcome within this vulnerable
group therefore is important. Delaying the moment of
surgery and with application of prehabilitation programs to
regain physical resources or preventive postoperative ICU
admissions may offer advantages for patients who are
identified as high risk for poor outcome. During this study,
patients who were diagnosed with and treated for esopha-
geal cancer received standard care. Regarding physical
activity, this means that they have received physical ther-
apy during their hospital admission, but no additional
physical intervention was provided.
The inability of a hospital to let patients with severe
complications survive is known as failure to rescue (FTR).
Instead of higher complication rates, higher FTR rates are
the main determinant of postoperative mortality.21 FTR
variability between hospitals is largely contributed to
hospital-related factors, such as the available level of ICU
care.22 On the other hand, variability of patient character-
istics influences FTR rates as well.23 The amount of muscle
mass lost during neoadjuvant CRT could be used as a
predictor of FTR rates in future studies.
Our data are in line with several studies. Deans and
colleagues showed that weight loss, among others, was
independently predictive of death after esophageal resec-
tions.24 This study focused on long-term mortality (disease
prognosis); therefore, weight loss may actually be a re-
flection of tumor progression rather than functional
depletion. In their recent study, Awad et al. showed a de-
crease in muscle mass during CRT as measured on the L3
level on CT scans, although a correlation with adverse
postoperative outcome could not be found.5 Patients with
advanced tumors were not analyzed separately from those
with local tumors, as in the current study.
As with every observational study, the current data
should be taken with caution. Although the studied cohort
was relatively large, numbers of complication-related
deaths are small. Therefore, the observed effect should be
validated in a larger, preferably multicenter or nationwide
cohort. Second, sarcopenia rates were relatively high in this
study using the predefined cutoff values that remain subject
to debate. It is desirable to define cutoff values based on
different cancer type populations. Finally, muscle and fat
loss are only one aspect of functional depletion. Other
parameters, such as loss of muscle function and strength,
were not measured in this study. This is unfortunate, be-
cause a recent report showed that function tests may assess
muscle quality, making their relationship with prognosis
potentially better than that of muscle mass.25
It should be addressed whether attempts to attenuate loss
of muscle mass during neoadjuvant CRT are effective and
whether they result in decreased FTR rates. In the studied
population, efforts to counteract exhaustion of physiologic
reserves by nutritional support were already done, indi-
cating that nutrition alone is not the key to success. Several
systematic reviews and meta-analyses have concluded that
physical exercise may improve physical functioning and
overall quality of life in cancer patients.26,27 Strength
training is the most effective exercise to slow down the rate
of loss of muscle mass and maintaining and improving
muscle strength. The combination of physical exercise with
essential amino acid ingestion elicits the greatest anabolic
response.28,29 Because physical exercise is only effective in
terms of improving muscle strength when performed
2–3 days a week, the feasibility of this approach in com-
bination with the physical and mental side-effects of
neoadjuvant CRT should be determined.30 Finally, eicos-
apentaenoic acid (EPA) can preserve lean body mass after
esophageal surgery and therefore may be an interesting
option to preserve muscle mass during CRT.31
Complete cohort (n=123)
Not receiving CRT (n=9) Receiving CRT (n=114)
Pre CRT scan available (n=108) Post CRT scan available (n=102)
Both pre and post CRT
scan available (n=96)
DIAGRAM 1 Proportion of patients having preCRT and postCRT
scans
TABLE 3 Body composition measures











preCRT 2 (2 %)
postCRT 2 (2 %)
Sarcopenic visceral obesity
preCRT 16 (17 %)
postCRT 20 (21 %)
Height and weight values used for all calculations were recorded at
time of diagnosis
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